
Despite decades of investigation, Alzheimer’s remains one of medicine’s great unsolved problems.
Copyright 2018 The Associated Press. All Rights Reserved
Swiss drugmaker Roche has joined a push to halt the disease in its tracks. Can it succeed?
Carole Greig was working as a companion to women living with dementia when she began to experience problems with her own short-term memory.
The 71-year-old former bank employee was herself diagnosed with Alzheimer’s disease in 2023: a terrible shock to which she mounted a determined response.
This year she enrolled in a major trial by Swiss drugmaker Roche looking at whether a new treatment can halt the progression of Alzheimer’s, the most common form of dementia, which affects tens of millions of people globally and has no known cure.
“It’s one of the best decisions I’ve ever made,” Greig said. “Confusion, anxiety and organisational skills, it’s those problems I’m experiencing . . . Not only does [the trial] keep me abreast of what’s happening, I know that I’m being fully monitored and that really reassures me.”
External Content
Despite decades of investigation, Alzheimer’s remains one of medicine’s great unsolved problems. New drugs have modestly slowed the progression of the condition but proved unable to halt or reverse it.
Now Roche has joined companies including Eli Lilly pushing into a new frontier of research – testing whether treatments can not only stave off cognitive decline but prevent symptoms from ever emerging in the first place.
Shuttle into the brain
Greig is one of more than 1,000 patients taking part in a late-stage trial for trontinemab – a treatment designed to clear the amyloid plaques that accumulate in the brains of people with Alzheimer’s and trigger processes fatal to nerve cells.
The trial – due to report its first results in 2028 – is aiming to overcome a fundamental issue with the existing generation of amyloid-targeting drugs: getting enough of the molecule into the brain.
Roche’s new drug is engineered to more effectively cross a protective layer of cells in the brain called the blood-brain barrier, which prevents harmful substances from entering the central nervous system. Its so-called Brainshuttle technology enables its anti-amyloid antibody to hitch a ride through the barrier by binding it to receptors that transport iron into the brain.
More

More
Switzerland’s bitter-sweet news for Alzheimer’s patients
Catherine Mummery, chief investigator for Roche’s trial at London’s National Hospital for Neurology and Neurosurgery, said the mechanism prevented the drug from “diffusing into the brain” uncontrolled, and instead “distributes it much more evenly”.
Existing Alzheimer’s treatments based on monoclonal antibodies – lab-made proteins designed to trigger an immune system response – can struggle to reach the brain at all. The blood-brain barrier prevented all but about 0.1% of them from penetrating, Mummery said. As a result, patients are given high doses of the drugs, which can cause serious side effects including brain swelling and bleeding. “That’s a lot of drug you’re giving for a little bit to get into [the brain],” she said.
Roche began enrolling patients in late-stage studies for trontinemab last year following promising early evidence that it could remove plaques far quicker than previous treatments. Data from an early-stage trial showed the drug, which is delivered via a drip, cleared amyloid plaque to below detectable levels in nine out of 10 patients in just 28 weeks – destroying a build-up that typically takes between 15-20 years to form.
“What success looks like is if we can steer patients towards a substantially slower rate of disease worsening,” said Geoffrey Kerchner, global head of neurodegeneration at Roche.
Growing burden of disease
The drugmaker is part of a race to find a cure for a disease that has rapidly become one of the world’s biggest public health crises. More than 55 million people were living with dementia in 2020 according to Alzheimer’s Disease International, a figure set to almost double every 20 years to reach 139 million in 2050, presenting a major challenge for healthcare systems and public finances around the world.
That also translates into a major financial opportunity: GlobalData forecasts the market for Alzheimer’s treatment could be worth $14.7 billion (CHF12.29 billion) across eight major markets by 2033, from $2.4 billion in 2023. Groups including Eli Lilly, Eisai, Biogen, Johnson & Johnson and AbbVie are all vying to develop effective treatments, with only Lilly and the partnership between Eisai and Biogen having brought disease-modifying drugs to market.
Roche believes its drug could generate over CHF3 billion ($3.7bn) in peak annual sales. However, its crucial test will be the extent to which removing amyloid plaques will halt the memory loss, disorientation and other symptoms associated with the disease. The generation of treatments from Lilly and the Eisai/Biogen partnership has not proved that hypothesis.
Both have been shown to remove substantial amounts of plaque and were considered a major breakthrough. But they only slow cognitive decline to a modest extent.
Eisai and Biogen’s lecanemab – approved in the US in 2023 and the UK the following year – slowed deterioration by 27% over 18 months compared with a placebo in clinical trials. Eli Lilly’s donanemab slowed deterioration by 29% in a separate study.
More

More
Medicines regulators weigh hope and hype with new Alzheimer’s drugs
Siddharthan Chandran, director of the UK government-backed Dementia Research Institute, said the treatments were helping to drive the “beginnings of a revolution” in dealing with Alzheimer’s. They showed for the first time that an intervention could “deliver objective, quantifiable change in measures that we know are biologically and clinically relevant”.
But both drugs also come with significant potential side effects, and are costly and complex to administer. Neither is routinely available on prescription in the UK after the National Institute for Health and Care Excellence concluded the benefits were “too small to justify the significant cost to the NHS” – a decision it is reviewing on appeal. “All of the innovation in the world is no good unless it actually benefits patients,” said Susan Kohlhaas of Alzheimer’s Research UK.
Lilly’s donanemab (sold as Kisunla) costs about $32,000 a year in the US, with additional costs for scans and aftercare, though both drugs are covered by Medicare for eligible patients. Global sales of donanemab reached $193 million in the third quarter, up 175% year on year while sales of lecanemab (sold as Leqembi) hit $202 million, up 67%.
The relatively small impact on cognitive decline underlines the complexity of treating Alzheimer’s, the causes of which are not fully understood. Although scientists have identified the build-up of two proteins – amyloid and tau – as important, other factors including genetics also play a role. Patients still suffer from Alzheimer’s even when amyloid plaques are cleared, while some people with amyloid plaques never develop the condition at all.
Those uncertainties have prompted researchers to pursue an increasingly diverse array of targets. Currently 158 experimental drugs for Alzheimer’s are being investigated across 192 clinical trials, according to research published this year. Of those, amyloid-targeting drugs made up 20% of the pipeline, down from a third a decade ago, while treatments designed to address tau, reduce inflammation or rebalance the immune system have risen sharply.
Roche is also one of a growing number of companies working on technologies to better transport drugs to the brain. This year US-based Denali became the first group to secure US regulatory approval for a biologic drug specifically designed to cross the blood-brain barrier, with its treatment for Hunter syndrome.
Dublin-based Aerska is developing a similar technology. “This is a watershed moment for treating brain diseases,” said chief executive Jack O’Meara. “Any brain disease you can think of, there’s someone now working on a shuttled product for that.”
More targeted treatments will not solve a separate issue with Alzheimer’s drugs, however – that they often arrive too late. By the time patients start experiencing memory problems, years of damage may have already occurred in the brain.
Preventing before symptoms start
That is where Roche’s more ambitious goal comes in. It is examining whether its new treatment could prevent people at higher risk of the disease from ever developing Alzheimer’s symptoms at all.
In September the Swiss group began recruiting UK participants for a late-stage trial of 1,600 people worldwide aged 55 to 80 with no symptoms but at higher risk of developing the condition, to find out whether administering trontinemab could prevent or delay its onset.
The Preventron trial, expected to run until 2032, hinges on a major advancement in the form of a new blood test designed to identify people with high levels of the pTau217 protein, a biomarker of Alzheimer’s pathology. The test – developed by Roche in partnership with Lilly – can provide results in only 18 minutes and could reduce reliance on existing diagnostic methods including costly PET scans and invasive lumbar punctures.
“Only a few years ago the idea we could have a blood test for Alzheimer’s was really science fiction,” said Ashton Harper, global medical director for neurosciences at Roche’s diagnostics division.
The company is joining Lilly, Eisai and Biogen looking at whether their drugs could work preventively. Lilly could report its first results from a trial in higher risk people without symptoms as soon as next year, while the latter partnership expect findings from their own study in 2028. But Roche has generated interest thanks to its advancements in diagnostics combined with its Brainshuttle technology.
The prospect of a future in which people can be screened for dementia as easily as having their blood pressure or cholesterol tested is exciting researchers. But it will be many years before scientists know whether early diagnosis and a new generation of treatments can really change the course of the disease.
Meanwhile Greig has more uncertainty to deal with. Neither she nor Roche’s researchers know if she is taking a placebo or the real drug. But taking part in the trial has given her hope.
“I hope I’m on trontinemab but whatever it is . . . I’m keeping in control for the moment.”
Additional reporting by Patrick Temple-West
Copyright The Financial Times Limited 2026

